Search research articles
Contact Us
Filters
Showing results (1-10 of 30) with videos related to
Page
of 3
Sort By:
Fund Raising Management
|
November 7, 1982
How to budget the fund raising process
R E Stoll
Progress in Clinical and Biological Research
|
January 1, 1987
The preclinical development of biotechnology-derived pharmaceuticals: the PMA perspective. Pharmaceutical Manufacturers Association
R E Stoll
Toxicologic Pathology
|
August 26, 1998
Cancer hazard identification: toward simplification and interpretability
R E Stoll
Environmental and Molecular Mutagenesis
|
February 15, 2001
Transgenic assays and the identification of carcinogens
R Tennant, J Haseman, R E Stoll
Psychopharmacology
|
May 5, 1976
Barbital alteration of central nervous system sensitivity to hexobarbital in the rat
R C Schnell, R E Stoll, T D Prosser
Life Sciences
|
August 1, 1974
Possible role of pheromones in modifying drug response in the mouse
R E Stoll, R M Paolino, W F Bousquet
Toxicologic Pathology
|
October 21, 1999
Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens
H E Holden, R E Stoll, K T Blanchard
Metabolism: Clinical and Experimental
|
March 1, 1973
The chick as a laboratory model for the study of estrogen-induced hyperlipidemia
D J Kudzma, P M Hegstad, R E Stoll
Lens and Eye Toxicity Research
|
January 1, 1990
Post-mortem biochemistry of beagle dog lenses after treatment with Fluvastatin (Sandoz) for 2 years at different dose levels
O Hockwin, M Evans, S A Roberts, et al.
American Journal of Veterinary Research
|
December 7, 2000
Hemodynamic and electrophysiologic effects of ontazolast in dogs
R L Hamlin, T Nakayama, J T Brady, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 30) with videos related to
Sort By:
Page
of 3
Fund Raising Management
|
November 7, 1982
How to budget the fund raising process
R E Stoll
Progress in Clinical and Biological Research
|
January 1, 1987
The preclinical development of biotechnology-derived pharmaceuticals: the PMA perspective. Pharmaceutical Manufacturers Association
R E Stoll
Toxicologic Pathology
|
August 26, 1998
Cancer hazard identification: toward simplification and interpretability
R E Stoll
Environmental and Molecular Mutagenesis
|
February 15, 2001
Transgenic assays and the identification of carcinogens
R Tennant, J Haseman, R E Stoll
Psychopharmacology
|
May 5, 1976
Barbital alteration of central nervous system sensitivity to hexobarbital in the rat
R C Schnell, R E Stoll, T D Prosser
Life Sciences
|
August 1, 1974
Possible role of pheromones in modifying drug response in the mouse
R E Stoll, R M Paolino, W F Bousquet
Toxicologic Pathology
|
October 21, 1999
Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens
H E Holden, R E Stoll, K T Blanchard
Metabolism: Clinical and Experimental
|
March 1, 1973
The chick as a laboratory model for the study of estrogen-induced hyperlipidemia
D J Kudzma, P M Hegstad, R E Stoll
Lens and Eye Toxicity Research
|
January 1, 1990
Post-mortem biochemistry of beagle dog lenses after treatment with Fluvastatin (Sandoz) for 2 years at different dose levels
O Hockwin, M Evans, S A Roberts, et al.
American Journal of Veterinary Research
|
December 7, 2000
Hemodynamic and electrophysiologic effects of ontazolast in dogs
R L Hamlin, T Nakayama, J T Brady, et al.
Page
of 3